Publications

ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

Download PDF
Resource: ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for 1 Pancreatic Ductal Adenocarcinoma

.

Related Articles

Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer

Link

Downregulation of LATS1/2 Drives Endothelial Senescence-Associated Stemness (SAS) and Atherothrombotic Lesion Formation

Link